SCHEMBL23713158

SCHEMBL23713158

NC(=S)NNC(O)c1ccccc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPT P10636 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ GAA P10253 3/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MAPK8 P45983 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ PTGS1 P23219 2/20 0.36
▸ RAB9A P51151 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ RXFP1 Q9HBX9 2/20 0.35
▸ AKR1C3 P42330 1/20 0.35
▸ AKR1C2 P52895 1/20 0.35
▸ SIRT2 Q8IXJ6 1/20 0.35
▸ TRPA1 O75762 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22571349 0.81 MAPT (0.43) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL23713159 0.78 MAPT (0.44) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL25543231 0.75 MEN1 (0.44) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL22556306 0.74 RXFP1 (0.53) KIF11GAAMAPK8PTGS1RAB9A
SCHEMBL23713157 0.72 MEN1 (0.42) KIF11ALDH1A1MAPTMEN1KMT2A
SCHEMBL1921457 0.71 ALDH1A1 (0.55) KIF11ALDH1A1MAPTMEN1KMT2A
SCHEMBL22571369 0.70 SIRT2 (0.62) MAPK8PTGS1RXFP1SIRT2
SCHEMBL21764748 0.70 RXFP1 (0.47) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL23713109 0.69 P2RY1 (0.35) MAPTMEN1KMT2AKDM4EMAPK8
SCHEMBL25279533 0.67 AKR1C3 (0.60) MAPTMEN1KMT2AMAPK8PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 KIF11 2552/4885ALDH1A1 2353/4885MAPT 2455/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 KIF11 2552/4885ALDH1A1 2353/4885MAPT 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback